• $3,299.00
    Market Cap
  • 200.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2021
Income Statement
Total Operating Revenue
41,780
N/A
Cost of Revenue
2.4M
N/A
Gross Profit
-2.3M
N/A
Sales and Marketing Expense
N/A
N/A
Research and Development Expense
N/A
N/A
Depreciation and Amortization Expense
12,137
N/A
Total Operating Expenses
5.1M
N/A
Operating Profit
-7.4M
N/A
Interest Income
8,976
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
8,976
N/A
Total Nonoperating Income and Expense
214,058
N/A
Income before Taxes
-7.4M
N/A
Income Taxes
-1.8M
N/A
Extraordinary Items
2.8M
N/A
Net Income
-7.2M
N/A
Net Income from Continuing Operations Applicable to Common
-7.2M
N/A
Basic EPS and Net Income
-0.66
N/A
Diluted EPS and Net Income
-0.66
N/A
Basic Weighted Average Shares
11.0M
N/A
Diluted Weighted Average Shares
11.0M
N/A
Balance Sheet
Cash and Cash Equivalents
1.6M
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
1.6M
N/A
Total Current Assets
3.8M
N/A
Accumulated Depreciation
12,137
N/A
Property and Plant and Equipment and Net
483,100
N/A
Total Long-Term Assets
483,100
N/A
Total Assets
44.6M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
0
N/A
Total Current Liabilities
4.1M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
38.7M
N/A
Total Liabilities
42.7M
N/A
Retained Earnings
-50.5M
N/A
Total Stockholders Equity
1.9M
N/A
Total Shares Outstanding
11.0M
N/A
Cash Flow
Cash from Operating Activities
-5.6M
N/A
Capital Expenditures
355,740
N/A
Cash from Investing Activities
5.3M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
29,871
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow